Medical Care
Global Drugs to Treat Urea Cycle Disorders Market Research Report 2025
- May 12, 25
- ID: 235088
- Pages: 89
- Figures: 83
- Views: 7
The global market for Drugs to Treat Urea Cycle Disorders was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Drugs to Treat Urea Cycle Disorders is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Drugs to Treat Urea Cycle Disorders is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Drugs to Treat Urea Cycle Disorders in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Drugs to Treat Urea Cycle Disorders include Horizon Therapeutics Plc, Bausch Health Companies Inc., Recordati Rare Diseases Inc., Nestle S.A., Danone S.A., Lucane Pharma SA, Acer Therapeutics Inc., Ultragenyx Pharmaceutical, Aeglea Biotherapeutics, Inc, Arcturus Therapeutics Holdings Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Drugs to Treat Urea Cycle Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs to Treat Urea Cycle Disorders.
The Drugs to Treat Urea Cycle Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs to Treat Urea Cycle Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs to Treat Urea Cycle Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Horizon Therapeutics Plc
Bausch Health Companies Inc.
Recordati Rare Diseases Inc.
Nestle S.A.
Danone S.A.
Lucane Pharma SA
Acer Therapeutics Inc.
Ultragenyx Pharmaceutical
Aeglea Biotherapeutics, Inc
Arcturus Therapeutics Holdings Inc.
Orpharma Pty Ltd.
Selecta Biosciences, Inc.
Abbott
Mead Johnson & Company, LLC
Segment by Type
Oral Drugs
Injection of Drugs
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs to Treat Urea Cycle Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Drugs to Treat Urea Cycle Disorders is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Drugs to Treat Urea Cycle Disorders is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Drugs to Treat Urea Cycle Disorders in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Drugs to Treat Urea Cycle Disorders include Horizon Therapeutics Plc, Bausch Health Companies Inc., Recordati Rare Diseases Inc., Nestle S.A., Danone S.A., Lucane Pharma SA, Acer Therapeutics Inc., Ultragenyx Pharmaceutical, Aeglea Biotherapeutics, Inc, Arcturus Therapeutics Holdings Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Drugs to Treat Urea Cycle Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs to Treat Urea Cycle Disorders.
The Drugs to Treat Urea Cycle Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs to Treat Urea Cycle Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs to Treat Urea Cycle Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Horizon Therapeutics Plc
Bausch Health Companies Inc.
Recordati Rare Diseases Inc.
Nestle S.A.
Danone S.A.
Lucane Pharma SA
Acer Therapeutics Inc.
Ultragenyx Pharmaceutical
Aeglea Biotherapeutics, Inc
Arcturus Therapeutics Holdings Inc.
Orpharma Pty Ltd.
Selecta Biosciences, Inc.
Abbott
Mead Johnson & Company, LLC
Segment by Type
Oral Drugs
Injection of Drugs
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs to Treat Urea Cycle Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Drugs
1.2.3 Injection of Drugs
1.3 Market by Application
1.3.1 Global Drugs to Treat Urea Cycle Disorders Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs to Treat Urea Cycle Disorders Market Perspective (2020-2031)
2.2 Global Drugs to Treat Urea Cycle Disorders Growth Trends by Region
2.2.1 Global Drugs to Treat Urea Cycle Disorders Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs to Treat Urea Cycle Disorders Historic Market Size by Region (2020-2025)
2.2.3 Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Region (2026-2031)
2.3 Drugs to Treat Urea Cycle Disorders Market Dynamics
2.3.1 Drugs to Treat Urea Cycle Disorders Industry Trends
2.3.2 Drugs to Treat Urea Cycle Disorders Market Drivers
2.3.3 Drugs to Treat Urea Cycle Disorders Market Challenges
2.3.4 Drugs to Treat Urea Cycle Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs to Treat Urea Cycle Disorders Players by Revenue
3.1.1 Global Top Drugs to Treat Urea Cycle Disorders Players by Revenue (2020-2025)
3.1.2 Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Players (2020-2025)
3.2 Global Drugs to Treat Urea Cycle Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs to Treat Urea Cycle Disorders Revenue
3.4 Global Drugs to Treat Urea Cycle Disorders Market Concentration Ratio
3.4.1 Global Drugs to Treat Urea Cycle Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs to Treat Urea Cycle Disorders Revenue in 2024
3.5 Global Key Players of Drugs to Treat Urea Cycle Disorders Head office and Area Served
3.6 Global Key Players of Drugs to Treat Urea Cycle Disorders, Product and Application
3.7 Global Key Players of Drugs to Treat Urea Cycle Disorders, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs to Treat Urea Cycle Disorders Breakdown Data by Type
4.1 Global Drugs to Treat Urea Cycle Disorders Historic Market Size by Type (2020-2025)
4.2 Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Type (2026-2031)
5 Drugs to Treat Urea Cycle Disorders Breakdown Data by Application
5.1 Global Drugs to Treat Urea Cycle Disorders Historic Market Size by Application (2020-2025)
5.2 Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
6.2 North America Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
6.4 North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
7.2 Europe Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
7.4 Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
8.2 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
9.2 Latin America Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
9.4 Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
10.2 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Horizon Therapeutics Plc
11.1.1 Horizon Therapeutics Plc Company Details
11.1.2 Horizon Therapeutics Plc Business Overview
11.1.3 Horizon Therapeutics Plc Drugs to Treat Urea Cycle Disorders Introduction
11.1.4 Horizon Therapeutics Plc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.1.5 Horizon Therapeutics Plc Recent Development
11.2 Bausch Health Companies Inc.
11.2.1 Bausch Health Companies Inc. Company Details
11.2.2 Bausch Health Companies Inc. Business Overview
11.2.3 Bausch Health Companies Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.2.4 Bausch Health Companies Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.2.5 Bausch Health Companies Inc. Recent Development
11.3 Recordati Rare Diseases Inc.
11.3.1 Recordati Rare Diseases Inc. Company Details
11.3.2 Recordati Rare Diseases Inc. Business Overview
11.3.3 Recordati Rare Diseases Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.3.4 Recordati Rare Diseases Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.3.5 Recordati Rare Diseases Inc. Recent Development
11.4 Nestle S.A.
11.4.1 Nestle S.A. Company Details
11.4.2 Nestle S.A. Business Overview
11.4.3 Nestle S.A. Drugs to Treat Urea Cycle Disorders Introduction
11.4.4 Nestle S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.4.5 Nestle S.A. Recent Development
11.5 Danone S.A.
11.5.1 Danone S.A. Company Details
11.5.2 Danone S.A. Business Overview
11.5.3 Danone S.A. Drugs to Treat Urea Cycle Disorders Introduction
11.5.4 Danone S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.5.5 Danone S.A. Recent Development
11.6 Lucane Pharma SA
11.6.1 Lucane Pharma SA Company Details
11.6.2 Lucane Pharma SA Business Overview
11.6.3 Lucane Pharma SA Drugs to Treat Urea Cycle Disorders Introduction
11.6.4 Lucane Pharma SA Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.6.5 Lucane Pharma SA Recent Development
11.7 Acer Therapeutics Inc.
11.7.1 Acer Therapeutics Inc. Company Details
11.7.2 Acer Therapeutics Inc. Business Overview
11.7.3 Acer Therapeutics Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.7.4 Acer Therapeutics Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.7.5 Acer Therapeutics Inc. Recent Development
11.8 Ultragenyx Pharmaceutical
11.8.1 Ultragenyx Pharmaceutical Company Details
11.8.2 Ultragenyx Pharmaceutical Business Overview
11.8.3 Ultragenyx Pharmaceutical Drugs to Treat Urea Cycle Disorders Introduction
11.8.4 Ultragenyx Pharmaceutical Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.8.5 Ultragenyx Pharmaceutical Recent Development
11.9 Aeglea Biotherapeutics, Inc
11.9.1 Aeglea Biotherapeutics, Inc Company Details
11.9.2 Aeglea Biotherapeutics, Inc Business Overview
11.9.3 Aeglea Biotherapeutics, Inc Drugs to Treat Urea Cycle Disorders Introduction
11.9.4 Aeglea Biotherapeutics, Inc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.9.5 Aeglea Biotherapeutics, Inc Recent Development
11.10 Arcturus Therapeutics Holdings Inc.
11.10.1 Arcturus Therapeutics Holdings Inc. Company Details
11.10.2 Arcturus Therapeutics Holdings Inc. Business Overview
11.10.3 Arcturus Therapeutics Holdings Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.10.4 Arcturus Therapeutics Holdings Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.10.5 Arcturus Therapeutics Holdings Inc. Recent Development
11.11 Orpharma Pty Ltd.
11.11.1 Orpharma Pty Ltd. Company Details
11.11.2 Orpharma Pty Ltd. Business Overview
11.11.3 Orpharma Pty Ltd. Drugs to Treat Urea Cycle Disorders Introduction
11.11.4 Orpharma Pty Ltd. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.11.5 Orpharma Pty Ltd. Recent Development
11.12 Selecta Biosciences, Inc.
11.12.1 Selecta Biosciences, Inc. Company Details
11.12.2 Selecta Biosciences, Inc. Business Overview
11.12.3 Selecta Biosciences, Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.12.4 Selecta Biosciences, Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.12.5 Selecta Biosciences, Inc. Recent Development
11.13 Abbott
11.13.1 Abbott Company Details
11.13.2 Abbott Business Overview
11.13.3 Abbott Drugs to Treat Urea Cycle Disorders Introduction
11.13.4 Abbott Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.13.5 Abbott Recent Development
11.14 Mead Johnson & Company, LLC
11.14.1 Mead Johnson & Company, LLC Company Details
11.14.2 Mead Johnson & Company, LLC Business Overview
11.14.3 Mead Johnson & Company, LLC Drugs to Treat Urea Cycle Disorders Introduction
11.14.4 Mead Johnson & Company, LLC Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.14.5 Mead Johnson & Company, LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Drugs
1.2.3 Injection of Drugs
1.3 Market by Application
1.3.1 Global Drugs to Treat Urea Cycle Disorders Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs to Treat Urea Cycle Disorders Market Perspective (2020-2031)
2.2 Global Drugs to Treat Urea Cycle Disorders Growth Trends by Region
2.2.1 Global Drugs to Treat Urea Cycle Disorders Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs to Treat Urea Cycle Disorders Historic Market Size by Region (2020-2025)
2.2.3 Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Region (2026-2031)
2.3 Drugs to Treat Urea Cycle Disorders Market Dynamics
2.3.1 Drugs to Treat Urea Cycle Disorders Industry Trends
2.3.2 Drugs to Treat Urea Cycle Disorders Market Drivers
2.3.3 Drugs to Treat Urea Cycle Disorders Market Challenges
2.3.4 Drugs to Treat Urea Cycle Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs to Treat Urea Cycle Disorders Players by Revenue
3.1.1 Global Top Drugs to Treat Urea Cycle Disorders Players by Revenue (2020-2025)
3.1.2 Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Players (2020-2025)
3.2 Global Drugs to Treat Urea Cycle Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs to Treat Urea Cycle Disorders Revenue
3.4 Global Drugs to Treat Urea Cycle Disorders Market Concentration Ratio
3.4.1 Global Drugs to Treat Urea Cycle Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs to Treat Urea Cycle Disorders Revenue in 2024
3.5 Global Key Players of Drugs to Treat Urea Cycle Disorders Head office and Area Served
3.6 Global Key Players of Drugs to Treat Urea Cycle Disorders, Product and Application
3.7 Global Key Players of Drugs to Treat Urea Cycle Disorders, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs to Treat Urea Cycle Disorders Breakdown Data by Type
4.1 Global Drugs to Treat Urea Cycle Disorders Historic Market Size by Type (2020-2025)
4.2 Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Type (2026-2031)
5 Drugs to Treat Urea Cycle Disorders Breakdown Data by Application
5.1 Global Drugs to Treat Urea Cycle Disorders Historic Market Size by Application (2020-2025)
5.2 Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
6.2 North America Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
6.4 North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
7.2 Europe Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
7.4 Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
8.2 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
9.2 Latin America Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
9.4 Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size (2020-2031)
10.2 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Horizon Therapeutics Plc
11.1.1 Horizon Therapeutics Plc Company Details
11.1.2 Horizon Therapeutics Plc Business Overview
11.1.3 Horizon Therapeutics Plc Drugs to Treat Urea Cycle Disorders Introduction
11.1.4 Horizon Therapeutics Plc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.1.5 Horizon Therapeutics Plc Recent Development
11.2 Bausch Health Companies Inc.
11.2.1 Bausch Health Companies Inc. Company Details
11.2.2 Bausch Health Companies Inc. Business Overview
11.2.3 Bausch Health Companies Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.2.4 Bausch Health Companies Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.2.5 Bausch Health Companies Inc. Recent Development
11.3 Recordati Rare Diseases Inc.
11.3.1 Recordati Rare Diseases Inc. Company Details
11.3.2 Recordati Rare Diseases Inc. Business Overview
11.3.3 Recordati Rare Diseases Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.3.4 Recordati Rare Diseases Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.3.5 Recordati Rare Diseases Inc. Recent Development
11.4 Nestle S.A.
11.4.1 Nestle S.A. Company Details
11.4.2 Nestle S.A. Business Overview
11.4.3 Nestle S.A. Drugs to Treat Urea Cycle Disorders Introduction
11.4.4 Nestle S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.4.5 Nestle S.A. Recent Development
11.5 Danone S.A.
11.5.1 Danone S.A. Company Details
11.5.2 Danone S.A. Business Overview
11.5.3 Danone S.A. Drugs to Treat Urea Cycle Disorders Introduction
11.5.4 Danone S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.5.5 Danone S.A. Recent Development
11.6 Lucane Pharma SA
11.6.1 Lucane Pharma SA Company Details
11.6.2 Lucane Pharma SA Business Overview
11.6.3 Lucane Pharma SA Drugs to Treat Urea Cycle Disorders Introduction
11.6.4 Lucane Pharma SA Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.6.5 Lucane Pharma SA Recent Development
11.7 Acer Therapeutics Inc.
11.7.1 Acer Therapeutics Inc. Company Details
11.7.2 Acer Therapeutics Inc. Business Overview
11.7.3 Acer Therapeutics Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.7.4 Acer Therapeutics Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.7.5 Acer Therapeutics Inc. Recent Development
11.8 Ultragenyx Pharmaceutical
11.8.1 Ultragenyx Pharmaceutical Company Details
11.8.2 Ultragenyx Pharmaceutical Business Overview
11.8.3 Ultragenyx Pharmaceutical Drugs to Treat Urea Cycle Disorders Introduction
11.8.4 Ultragenyx Pharmaceutical Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.8.5 Ultragenyx Pharmaceutical Recent Development
11.9 Aeglea Biotherapeutics, Inc
11.9.1 Aeglea Biotherapeutics, Inc Company Details
11.9.2 Aeglea Biotherapeutics, Inc Business Overview
11.9.3 Aeglea Biotherapeutics, Inc Drugs to Treat Urea Cycle Disorders Introduction
11.9.4 Aeglea Biotherapeutics, Inc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.9.5 Aeglea Biotherapeutics, Inc Recent Development
11.10 Arcturus Therapeutics Holdings Inc.
11.10.1 Arcturus Therapeutics Holdings Inc. Company Details
11.10.2 Arcturus Therapeutics Holdings Inc. Business Overview
11.10.3 Arcturus Therapeutics Holdings Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.10.4 Arcturus Therapeutics Holdings Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.10.5 Arcturus Therapeutics Holdings Inc. Recent Development
11.11 Orpharma Pty Ltd.
11.11.1 Orpharma Pty Ltd. Company Details
11.11.2 Orpharma Pty Ltd. Business Overview
11.11.3 Orpharma Pty Ltd. Drugs to Treat Urea Cycle Disorders Introduction
11.11.4 Orpharma Pty Ltd. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.11.5 Orpharma Pty Ltd. Recent Development
11.12 Selecta Biosciences, Inc.
11.12.1 Selecta Biosciences, Inc. Company Details
11.12.2 Selecta Biosciences, Inc. Business Overview
11.12.3 Selecta Biosciences, Inc. Drugs to Treat Urea Cycle Disorders Introduction
11.12.4 Selecta Biosciences, Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.12.5 Selecta Biosciences, Inc. Recent Development
11.13 Abbott
11.13.1 Abbott Company Details
11.13.2 Abbott Business Overview
11.13.3 Abbott Drugs to Treat Urea Cycle Disorders Introduction
11.13.4 Abbott Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.13.5 Abbott Recent Development
11.14 Mead Johnson & Company, LLC
11.14.1 Mead Johnson & Company, LLC Company Details
11.14.2 Mead Johnson & Company, LLC Business Overview
11.14.3 Mead Johnson & Company, LLC Drugs to Treat Urea Cycle Disorders Introduction
11.14.4 Mead Johnson & Company, LLC Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
11.14.5 Mead Johnson & Company, LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Injection of Drugs
Table 4. Global Drugs to Treat Urea Cycle Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Drugs to Treat Urea Cycle Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Drugs to Treat Urea Cycle Disorders Market Share by Region (2020-2025)
Table 8. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Drugs to Treat Urea Cycle Disorders Market Share by Region (2026-2031)
Table 10. Drugs to Treat Urea Cycle Disorders Market Trends
Table 11. Drugs to Treat Urea Cycle Disorders Market Drivers
Table 12. Drugs to Treat Urea Cycle Disorders Market Challenges
Table 13. Drugs to Treat Urea Cycle Disorders Market Restraints
Table 14. Global Drugs to Treat Urea Cycle Disorders Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Drugs to Treat Urea Cycle Disorders Market Share by Players (2020-2025)
Table 16. Global Top Drugs to Treat Urea Cycle Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs to Treat Urea Cycle Disorders as of 2024)
Table 17. Ranking of Global Top Drugs to Treat Urea Cycle Disorders Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Drugs to Treat Urea Cycle Disorders Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Drugs to Treat Urea Cycle Disorders, Headquarters and Area Served
Table 20. Global Key Players of Drugs to Treat Urea Cycle Disorders, Product and Application
Table 21. Global Key Players of Drugs to Treat Urea Cycle Disorders, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Drugs to Treat Urea Cycle Disorders Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Type (2020-2025)
Table 25. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Type (2026-2031)
Table 27. Global Drugs to Treat Urea Cycle Disorders Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Application (2020-2025)
Table 29. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Application (2026-2031)
Table 31. North America Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 46. Horizon Therapeutics Plc Company Details
Table 47. Horizon Therapeutics Plc Business Overview
Table 48. Horizon Therapeutics Plc Drugs to Treat Urea Cycle Disorders Product
Table 49. Horizon Therapeutics Plc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 50. Horizon Therapeutics Plc Recent Development
Table 51. Bausch Health Companies Inc. Company Details
Table 52. Bausch Health Companies Inc. Business Overview
Table 53. Bausch Health Companies Inc. Drugs to Treat Urea Cycle Disorders Product
Table 54. Bausch Health Companies Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 55. Bausch Health Companies Inc. Recent Development
Table 56. Recordati Rare Diseases Inc. Company Details
Table 57. Recordati Rare Diseases Inc. Business Overview
Table 58. Recordati Rare Diseases Inc. Drugs to Treat Urea Cycle Disorders Product
Table 59. Recordati Rare Diseases Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 60. Recordati Rare Diseases Inc. Recent Development
Table 61. Nestle S.A. Company Details
Table 62. Nestle S.A. Business Overview
Table 63. Nestle S.A. Drugs to Treat Urea Cycle Disorders Product
Table 64. Nestle S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 65. Nestle S.A. Recent Development
Table 66. Danone S.A. Company Details
Table 67. Danone S.A. Business Overview
Table 68. Danone S.A. Drugs to Treat Urea Cycle Disorders Product
Table 69. Danone S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 70. Danone S.A. Recent Development
Table 71. Lucane Pharma SA Company Details
Table 72. Lucane Pharma SA Business Overview
Table 73. Lucane Pharma SA Drugs to Treat Urea Cycle Disorders Product
Table 74. Lucane Pharma SA Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 75. Lucane Pharma SA Recent Development
Table 76. Acer Therapeutics Inc. Company Details
Table 77. Acer Therapeutics Inc. Business Overview
Table 78. Acer Therapeutics Inc. Drugs to Treat Urea Cycle Disorders Product
Table 79. Acer Therapeutics Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 80. Acer Therapeutics Inc. Recent Development
Table 81. Ultragenyx Pharmaceutical Company Details
Table 82. Ultragenyx Pharmaceutical Business Overview
Table 83. Ultragenyx Pharmaceutical Drugs to Treat Urea Cycle Disorders Product
Table 84. Ultragenyx Pharmaceutical Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 85. Ultragenyx Pharmaceutical Recent Development
Table 86. Aeglea Biotherapeutics, Inc Company Details
Table 87. Aeglea Biotherapeutics, Inc Business Overview
Table 88. Aeglea Biotherapeutics, Inc Drugs to Treat Urea Cycle Disorders Product
Table 89. Aeglea Biotherapeutics, Inc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 90. Aeglea Biotherapeutics, Inc Recent Development
Table 91. Arcturus Therapeutics Holdings Inc. Company Details
Table 92. Arcturus Therapeutics Holdings Inc. Business Overview
Table 93. Arcturus Therapeutics Holdings Inc. Drugs to Treat Urea Cycle Disorders Product
Table 94. Arcturus Therapeutics Holdings Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 95. Arcturus Therapeutics Holdings Inc. Recent Development
Table 96. Orpharma Pty Ltd. Company Details
Table 97. Orpharma Pty Ltd. Business Overview
Table 98. Orpharma Pty Ltd. Drugs to Treat Urea Cycle Disorders Product
Table 99. Orpharma Pty Ltd. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 100. Orpharma Pty Ltd. Recent Development
Table 101. Selecta Biosciences, Inc. Company Details
Table 102. Selecta Biosciences, Inc. Business Overview
Table 103. Selecta Biosciences, Inc. Drugs to Treat Urea Cycle Disorders Product
Table 104. Selecta Biosciences, Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 105. Selecta Biosciences, Inc. Recent Development
Table 106. Abbott Company Details
Table 107. Abbott Business Overview
Table 108. Abbott Drugs to Treat Urea Cycle Disorders Product
Table 109. Abbott Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 110. Abbott Recent Development
Table 111. Mead Johnson & Company, LLC Company Details
Table 112. Mead Johnson & Company, LLC Business Overview
Table 113. Mead Johnson & Company, LLC Drugs to Treat Urea Cycle Disorders Product
Table 114. Mead Johnson & Company, LLC Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 115. Mead Johnson & Company, LLC Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Drugs to Treat Urea Cycle Disorders Picture
Figure 2. Global Drugs to Treat Urea Cycle Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Drugs to Treat Urea Cycle Disorders Market Share by Type: 2024 VS 2031
Figure 4. Oral Drugs Features
Figure 5. Injection of Drugs Features
Figure 6. Global Drugs to Treat Urea Cycle Disorders Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Drugs to Treat Urea Cycle Disorders Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Specialty Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Drugs to Treat Urea Cycle Disorders Report Years Considered
Figure 12. Global Drugs to Treat Urea Cycle Disorders Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Drugs to Treat Urea Cycle Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Drugs to Treat Urea Cycle Disorders Market Share by Region: 2024 VS 2031
Figure 15. Global Drugs to Treat Urea Cycle Disorders Market Share by Players in 2024
Figure 16. Global Top Drugs to Treat Urea Cycle Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs to Treat Urea Cycle Disorders as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Drugs to Treat Urea Cycle Disorders Revenue in 2024
Figure 18. North America Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 20. United States Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 24. Germany Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Share by Region (2020-2031)
Figure 32. China Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 40. Mexico Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 44. Turkey Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Horizon Therapeutics Plc Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 48. Bausch Health Companies Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 49. Recordati Rare Diseases Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 50. Nestle S.A. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 51. Danone S.A. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 52. Lucane Pharma SA Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 53. Acer Therapeutics Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 54. Ultragenyx Pharmaceutical Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 55. Aeglea Biotherapeutics, Inc Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 56. Arcturus Therapeutics Holdings Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 57. Orpharma Pty Ltd. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 58. Selecta Biosciences, Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 59. Abbott Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 60. Mead Johnson & Company, LLC Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Injection of Drugs
Table 4. Global Drugs to Treat Urea Cycle Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Drugs to Treat Urea Cycle Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Drugs to Treat Urea Cycle Disorders Market Share by Region (2020-2025)
Table 8. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Drugs to Treat Urea Cycle Disorders Market Share by Region (2026-2031)
Table 10. Drugs to Treat Urea Cycle Disorders Market Trends
Table 11. Drugs to Treat Urea Cycle Disorders Market Drivers
Table 12. Drugs to Treat Urea Cycle Disorders Market Challenges
Table 13. Drugs to Treat Urea Cycle Disorders Market Restraints
Table 14. Global Drugs to Treat Urea Cycle Disorders Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Drugs to Treat Urea Cycle Disorders Market Share by Players (2020-2025)
Table 16. Global Top Drugs to Treat Urea Cycle Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs to Treat Urea Cycle Disorders as of 2024)
Table 17. Ranking of Global Top Drugs to Treat Urea Cycle Disorders Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Drugs to Treat Urea Cycle Disorders Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Drugs to Treat Urea Cycle Disorders, Headquarters and Area Served
Table 20. Global Key Players of Drugs to Treat Urea Cycle Disorders, Product and Application
Table 21. Global Key Players of Drugs to Treat Urea Cycle Disorders, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Drugs to Treat Urea Cycle Disorders Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Type (2020-2025)
Table 25. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Type (2026-2031)
Table 27. Global Drugs to Treat Urea Cycle Disorders Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Application (2020-2025)
Table 29. Global Drugs to Treat Urea Cycle Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Drugs to Treat Urea Cycle Disorders Revenue Market Share by Application (2026-2031)
Table 31. North America Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size by Country (2026-2031) & (US$ Million)
Table 46. Horizon Therapeutics Plc Company Details
Table 47. Horizon Therapeutics Plc Business Overview
Table 48. Horizon Therapeutics Plc Drugs to Treat Urea Cycle Disorders Product
Table 49. Horizon Therapeutics Plc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 50. Horizon Therapeutics Plc Recent Development
Table 51. Bausch Health Companies Inc. Company Details
Table 52. Bausch Health Companies Inc. Business Overview
Table 53. Bausch Health Companies Inc. Drugs to Treat Urea Cycle Disorders Product
Table 54. Bausch Health Companies Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 55. Bausch Health Companies Inc. Recent Development
Table 56. Recordati Rare Diseases Inc. Company Details
Table 57. Recordati Rare Diseases Inc. Business Overview
Table 58. Recordati Rare Diseases Inc. Drugs to Treat Urea Cycle Disorders Product
Table 59. Recordati Rare Diseases Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 60. Recordati Rare Diseases Inc. Recent Development
Table 61. Nestle S.A. Company Details
Table 62. Nestle S.A. Business Overview
Table 63. Nestle S.A. Drugs to Treat Urea Cycle Disorders Product
Table 64. Nestle S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 65. Nestle S.A. Recent Development
Table 66. Danone S.A. Company Details
Table 67. Danone S.A. Business Overview
Table 68. Danone S.A. Drugs to Treat Urea Cycle Disorders Product
Table 69. Danone S.A. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 70. Danone S.A. Recent Development
Table 71. Lucane Pharma SA Company Details
Table 72. Lucane Pharma SA Business Overview
Table 73. Lucane Pharma SA Drugs to Treat Urea Cycle Disorders Product
Table 74. Lucane Pharma SA Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 75. Lucane Pharma SA Recent Development
Table 76. Acer Therapeutics Inc. Company Details
Table 77. Acer Therapeutics Inc. Business Overview
Table 78. Acer Therapeutics Inc. Drugs to Treat Urea Cycle Disorders Product
Table 79. Acer Therapeutics Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 80. Acer Therapeutics Inc. Recent Development
Table 81. Ultragenyx Pharmaceutical Company Details
Table 82. Ultragenyx Pharmaceutical Business Overview
Table 83. Ultragenyx Pharmaceutical Drugs to Treat Urea Cycle Disorders Product
Table 84. Ultragenyx Pharmaceutical Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 85. Ultragenyx Pharmaceutical Recent Development
Table 86. Aeglea Biotherapeutics, Inc Company Details
Table 87. Aeglea Biotherapeutics, Inc Business Overview
Table 88. Aeglea Biotherapeutics, Inc Drugs to Treat Urea Cycle Disorders Product
Table 89. Aeglea Biotherapeutics, Inc Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 90. Aeglea Biotherapeutics, Inc Recent Development
Table 91. Arcturus Therapeutics Holdings Inc. Company Details
Table 92. Arcturus Therapeutics Holdings Inc. Business Overview
Table 93. Arcturus Therapeutics Holdings Inc. Drugs to Treat Urea Cycle Disorders Product
Table 94. Arcturus Therapeutics Holdings Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 95. Arcturus Therapeutics Holdings Inc. Recent Development
Table 96. Orpharma Pty Ltd. Company Details
Table 97. Orpharma Pty Ltd. Business Overview
Table 98. Orpharma Pty Ltd. Drugs to Treat Urea Cycle Disorders Product
Table 99. Orpharma Pty Ltd. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 100. Orpharma Pty Ltd. Recent Development
Table 101. Selecta Biosciences, Inc. Company Details
Table 102. Selecta Biosciences, Inc. Business Overview
Table 103. Selecta Biosciences, Inc. Drugs to Treat Urea Cycle Disorders Product
Table 104. Selecta Biosciences, Inc. Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 105. Selecta Biosciences, Inc. Recent Development
Table 106. Abbott Company Details
Table 107. Abbott Business Overview
Table 108. Abbott Drugs to Treat Urea Cycle Disorders Product
Table 109. Abbott Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 110. Abbott Recent Development
Table 111. Mead Johnson & Company, LLC Company Details
Table 112. Mead Johnson & Company, LLC Business Overview
Table 113. Mead Johnson & Company, LLC Drugs to Treat Urea Cycle Disorders Product
Table 114. Mead Johnson & Company, LLC Revenue in Drugs to Treat Urea Cycle Disorders Business (2020-2025) & (US$ Million)
Table 115. Mead Johnson & Company, LLC Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Drugs to Treat Urea Cycle Disorders Picture
Figure 2. Global Drugs to Treat Urea Cycle Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Drugs to Treat Urea Cycle Disorders Market Share by Type: 2024 VS 2031
Figure 4. Oral Drugs Features
Figure 5. Injection of Drugs Features
Figure 6. Global Drugs to Treat Urea Cycle Disorders Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Drugs to Treat Urea Cycle Disorders Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Specialty Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Drugs to Treat Urea Cycle Disorders Report Years Considered
Figure 12. Global Drugs to Treat Urea Cycle Disorders Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Drugs to Treat Urea Cycle Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Drugs to Treat Urea Cycle Disorders Market Share by Region: 2024 VS 2031
Figure 15. Global Drugs to Treat Urea Cycle Disorders Market Share by Players in 2024
Figure 16. Global Top Drugs to Treat Urea Cycle Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs to Treat Urea Cycle Disorders as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Drugs to Treat Urea Cycle Disorders Revenue in 2024
Figure 18. North America Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 20. United States Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 24. Germany Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Drugs to Treat Urea Cycle Disorders Market Share by Region (2020-2031)
Figure 32. China Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 40. Mexico Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Drugs to Treat Urea Cycle Disorders Market Share by Country (2020-2031)
Figure 44. Turkey Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Drugs to Treat Urea Cycle Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Horizon Therapeutics Plc Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 48. Bausch Health Companies Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 49. Recordati Rare Diseases Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 50. Nestle S.A. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 51. Danone S.A. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 52. Lucane Pharma SA Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 53. Acer Therapeutics Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 54. Ultragenyx Pharmaceutical Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 55. Aeglea Biotherapeutics, Inc Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 56. Arcturus Therapeutics Holdings Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 57. Orpharma Pty Ltd. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 58. Selecta Biosciences, Inc. Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 59. Abbott Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 60. Mead Johnson & Company, LLC Revenue Growth Rate in Drugs to Treat Urea Cycle Disorders Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232